Abstracts Archive - Page 287 of 2607 - ACR Meeting Abstracts

Abstract Number: 1489 • ACR Convergence 2024
Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy
H Michael Belmont¹, Brooke Cohen², Amit Saxena², Peter Izmirly³ and Jill Buyon⁴, ¹NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³New York University Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: LN treatment goal is to suppress immune mediated injury and preserve eGFR. Studies indicate proteinuria < 700 at 12 months predicts maintaining eGFR at…
Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Mary Jeffway¹, Feng Liu¹, Nancy Shadick¹, Michael Weinblatt², Brittany Weber³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ³Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Devin Driscoll¹, Navya George², S. Reza Jafarzadeh³, Christine Peloquin³, Jean Liew³ and Maureen Dubreuil⁴, ¹Boston Medical Center, Boston, MA, ²Boston University Medical Center Internal Medicine Residency Program, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
Abstract Number: 1501 • ACR Convergence 2024
Retrospective Cohort Study Identifying Pulmonary Complications in a Cohort of Patients with Systemic Lupus Erythematosus
Jessica Johnson¹, Chao Zhang² and Emily Littlejohn³, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cleveland Clinic, Cleveland Heights, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with multi organ involvement. One of the most common manifestations is pulmonary disease with a…
Abstract Number: 1473 • ACR Convergence 2024
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
M. Elaine Husni¹, Philip Mease², Dafna Gladman³, Barbara Ink⁴, Jérémy Lambert⁵, Patrick Healy⁶ and Laure Gossec⁷, ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Morrisville, NC, ⁷Sorbonne Université, Paris, France
Background/Purpose: PsA is characterized by joint and skin inflammation, and associated with debilitating symptoms of pain and fatigue.1 Previous research has shown that pain and…
Abstract Number: 1497 • ACR Convergence 2024
Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus
Justin Smith¹, Laura Patricia Whittall Garcia², Dennisse Bonilla², Qixuan Li², Robert Terbrueggen³, Hemani Wijesuriya³, Ian Richards³, Aviva Jacobs³, Joan Wither², Dafna Gladman⁴ and Zahi Touma⁵, and DxTerity, ¹University of Toronto, Toronto, AB, Canada, ²University Health Network, Toronto, ON, Canada, ³DxTerity Diagnostics Inc., Torrance, CA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I interferons (IFN) are pivotal in the pathogenesis of SLE, with studies showing high IFN gene signature (IGS) status associated with certain organ…
Abstract Number: 0325 • ACR Convergence 2024
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
Pitchaporn Yingchoncharoen¹, Nattanicha Chaisrimaneepan², Jerapas Thongpiya¹, Pojsakorn Danpanichkul¹ and Yanint Raksadawan³, ¹Texas Tech Health Sciences Center, Lubbock, TX, ²Texas Tech University Health Sciences Center, Lubbock, TX, ³Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Polymyositis and dermatomyositis (PM/DM) are subtypes of idiopathic inflammatory myopathies, belonging to the spectrum of polygenic autoimmune diseases Inflammatory bowel disease (IBD), encompassing ulcerative…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
Abstract Number: 1248 • ACR Convergence 2024
Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Shilpa Venkatachalam¹, Jeffrey Curtis², Anne Sydor³, Erik Stone⁴, Angela Degrassi³, Esteban Rivera⁵, Laura Stradford⁶ and Kelly Gavigan³, ¹Global Healthy Living Foundation, New York, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: Many people with inflammatory arthritis live with other serious chronic conditions that may affect their quality of life and ability to effectively manage their…
Abstract Number: 1512 • ACR Convergence 2024
Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: The systemic immune-inflammation index (SII) has been linked to inflammatory and immune responses, with research indicating its impact on rheumatoid arthritis (RA). However, its…
Abstract Number: 1492 • ACR Convergence 2024
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Edward Vital¹, Richard Furie², Eric Morand³, Ian Bruce⁴, Jacob Knagenhjelm⁵ and Catharina Lindholm⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ²Northwell Health, Manhasset, NY, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1377 • ACR Convergence 2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Adrián Quevedo-Rodríguez¹, Lucia Otero-Varela², Fernando Sánchez-Alonso³, Yanira Pérez-Vera¹, Javier Manero-Ruiz⁴, Cristina Campos-Fernández⁵, Sara Manrique-Arija⁶, Paloma Vela-Casasempere⁷, Antonio Mera-Varela⁸, César Díaz⁹, Atusa Movasat¹⁰, Blanca Garcia-Magallon¹¹, Inmaculada Ros-Vilamajó¹², Carolina Perez-Garcia¹³ and Isabel Castrejon¹⁴, and BIOBADASER working group., ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ¹²Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain
Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…
Abstract Number: 1506 • ACR Convergence 2024
Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery
Chrisanna Dobrowolski¹, Juan Pablo Diaz Martinez², Kathleen Bingham², Michelle Barraclough³, Roberta Kretzmann², Maria Carmela Tartaglia⁴, Lesley Ruttan⁵, May Choi⁶, Simone Appenzeller⁷, Sherief Marzouk², Dennisse Bonilla², Patti Katz⁸, Dorcas Beaton⁹, Robin Green², Joan Wither², Laura Patricia Whittall Garcia², Dafna Gladman¹⁰ and Zahi Touma¹¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²University Health Network, Toronto, ON, Canada, ³The University of Manchester, Manchester, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, SP, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus (SLE) has a well-established association with cognitive impairment (CI) and confers worse quality of life. We previously presented descriptive data regarding the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].